ArticlebioRxiv : the preprint server for biology2024
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance.
Tin Phan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.